How Long Can You Live With Cirrhosis and Kidney Failure?

Survival with both cirrhosis and kidney failure ranges from weeks to years, depending on how quickly the kidney injury develops, how severe the underlying liver disease is, and whether the person responds to treatment. At one extreme, the acute form of kidney failure tied to cirrhosis carries a median survival of roughly one month without intervention. At the other, people with a more slowly progressing kidney problem and less advanced liver disease can live close to a year or longer, especially if they respond to medication or reach transplantation. The wide gap makes the question impossible to answer with a single number, but the factors that push a person toward one end or the other are well understood.

Why Cirrhosis Causes Kidney Failure in the First Place

Most people think of the liver and kidneys as separate organs doing separate jobs. In advanced cirrhosis, they become tightly linked through a chain of blood-flow problems. High pressure in the portal vein (the main vessel feeding the liver) triggers the release of chemicals that widen blood vessels in the gut. That widening drops effective blood pressure elsewhere in the body. The kidneys interpret this as a signal that blood volume is dangerously low, so the body activates a cascade of stress hormones that clamp down on blood flow to the kidneys themselves.¹ The result is a severe drop in the kidneys’ filtering capacity even though, structurally, the kidney tissue may look normal under a microscope. This condition is called hepatorenal syndrome, or HRS, and it is the most feared form of kidney failure in cirrhosis patients.

Not all kidney problems in cirrhosis follow this pattern. Some people develop kidney damage from infections, from medications, from severe dehydration after gastrointestinal bleeding, or from longstanding conditions like diabetes that harm the kidney tissue directly. The cause of the kidney failure matters enormously for prognosis, because HRS is potentially reversible if liver function can be restored, while structural kidney damage often is not.²

Acute Versus Chronic Forms

Clinicians now split hepatorenal syndrome into two categories. The acute form, called AKI-HRS (acute kidney injury), comes on quickly and is the more dangerous of the two. Kidney function can deteriorate over just days. The chronic form, CKD-HRS, develops more slowly and tends to present with stubborn fluid retention and gradual worsening of kidney numbers over weeks to months.³ ⁴ The distinction is not just academic. It dictates how urgently treatment must begin and how long the person is likely to survive without a transplant.

What the Survival Numbers Look Like

The most cited prognostic data come from studies that tracked patients based on HRS type and their MELD score, a number that estimates how sick someone’s liver is using blood tests. In one well-known analysis, every patient with the acute form and a MELD score of 20 or higher had an extremely poor outcome, with a median survival of about one month. Patients with the chronic form fared better but still faced grim timelines: those with a MELD of 20 or above survived a median of about three months, while those with a MELD under 20 survived a median of roughly eleven months.⁵

Response to drug therapy shifts these numbers dramatically. A study of patients treated with vasoconstrictors found that those whose kidney function improved had a median overall survival of 29 months, compared to 8 months for those who did not respond.⁶ That gap underscores how important early, aggressive treatment is. Whether the kidneys respond to medication is one of the strongest signals doctors have about what comes next.

Factors That Push the Odds in One Direction

Beyond HRS type and MELD score, several other factors independently predict how long a person will live. In multivariate analyses, age, ongoing alcohol use, the duration of treatment received, and serum sodium levels all emerged as significant predictors.⁶ ² Patients with hepatic encephalopathy (confusion caused by toxins the liver can no longer clear) at the time kidney failure is diagnosed also do worse.²

In practical terms, a younger person whose liver disease is not alcohol-related, whose MELD score is under 20, and who responds to medication early has a meaningfully different trajectory from an older patient with active alcohol use, a MELD over 30, and no improvement in kidney numbers. The same diagnosis can mean months of relatively stable health or weeks of rapid decline.

What Triggers the Kidney Crisis

Kidney failure in cirrhosis rarely appears out of nowhere. The most common precipitating event is infection. In one study, infections triggered acute kidney injury in 60% of cases, followed by dehydration from gastrointestinal bleeding or gastroenteritis (about 20%) and refractory fluid buildup in the abdomen (about 16%).⁷ Spontaneous bacterial peritonitis, an infection of the abdominal fluid that commonly accompanies cirrhosis, is a particularly well-known trigger.⁸ Recognizing and treating these triggers quickly can sometimes prevent the full kidney syndrome from setting in.

Drug Therapy and How It Changes the Outlook

The main pharmacological strategy for HRS is giving a vasoconstrictor drug alongside intravenous albumin. The vasoconstrictor counteracts the gut-vessel widening that caused the problem, redirecting blood flow toward the kidneys. Albumin, a protein that expands blood volume, supports this by helping maintain blood pressure and improving blood flow through the kidney’s filtering units.⁹ ¹⁰

Terlipressin is the most studied vasoconstrictor for this purpose. In a randomized trial, about 44% of patients treated with terlipressin plus albumin showed improved kidney function, compared to roughly 9% of patients given albumin alone.¹¹ A head-to-head trial comparing terlipressin to an older combination of midodrine and octreotide found that about 70% of patients on terlipressin recovered kidney function, compared to roughly 29% on the alternative.¹² One complication is that the chronic form tends to relapse more frequently after initial improvement. In one study, HRS relapsed in half of chronic-type patients after terlipressin was stopped, compared to about 8% of acute-type patients.¹³

Albumin also plays a preventive role. When given alongside antibiotics during spontaneous bacterial peritonitis, albumin reduces the chance that kidney failure will develop in the first place.¹⁴

Procedures That Can Buy Time

For patients who do not respond to drugs or who relapse, a procedure called TIPS (transjugular intrahepatic portosystemic shunt) can sometimes rescue kidney function. TIPS creates a channel inside the liver that reroutes blood flow, reducing portal pressure and easing the hormonal cascade that starves the kidneys. In a systematic review and meta-analysis, the pooled rate of kidney function improvement after TIPS was about 93% in acute HRS and 83% across all types. Short-term survival was around 72% for acute HRS and 86% for chronic HRS; one-year survival was about 47% and 64%, respectively.¹⁵

TIPS is not without serious downsides. Nearly half of patients in pooled analyses developed hepatic encephalopathy afterward.¹⁵ And for patients whose kidneys are not yet severely impaired, a matched-cohort study found that TIPS offered a meaningful kidney-function boost only in those who started with notably reduced filtration rates; people with relatively preserved kidney function saw no significant benefit over standard drainage of abdominal fluid.¹⁶ The procedure is essentially a bridge: it can stabilize someone long enough to reach transplantation, but it is not a cure for either the liver or the kidney problem.

Transplantation as the Only Definitive Fix

Liver transplantation is the only treatment that addresses the root cause by replacing the failing liver and, in doing so, removing the hemodynamic cascade that caused kidney failure. For many HRS patients, kidney function recovers after a successful liver transplant. One study found that 84% of liver-transplant recipients who had met criteria for severe kidney impairment experienced kidney recovery after transplant. Sustained recovery lasting more than six months occurred in about 43%.¹⁷ The likelihood of lasting recovery was higher in patients whose kidney filtration rate had been above a certain threshold in the months before surgery, and lower in those who had spent a long time with severely reduced kidney function before transplant.

When kidney damage has become permanent, a simultaneous liver-kidney transplant (SLK) may be the better option. Under allocation policies implemented in the United States in 2017, patients who have been on dialysis for at least three months or who have advanced chronic kidney disease are prioritized for SLK. The system also includes a “safety net” that gives extra priority for a kidney transplant to liver-alone recipients whose kidneys do not bounce back after surgery. Early data show that one-year patient survival for safety-net kidney recipients was comparable to standard kidney-alone transplant recipients.¹⁸

However, not everyone reaches transplantation. Organ shortages, the patient’s overall fitness for surgery, continued substance use, and other factors all determine eligibility. For people who cannot be transplanted, the ceiling on survival is substantially lower.

When Multiple Organs Fail at Once

The worst-case scenario in cirrhosis is a syndrome called acute-on-chronic liver failure, or ACLF, where the liver and one or more other organs deteriorate rapidly at the same time. Kidney and liver failures are the two most common organ failures in ACLF, followed by problems with blood clotting, brain function, circulation, and breathing.¹⁹ The 28-day mortality for ACLF is around 30%, and the more organs that are failing, the worse the outlook becomes.¹⁹ ²⁰ ACLF is clinically distinct from a slow, gradual worsening of cirrhosis. It comes on suddenly, often triggered by an infection or a binge of alcohol, and it demands intensive care.

Managing Symptoms When the Situation Is Severe

Even when the underlying liver and kidney problems cannot be reversed, controlling complications makes a measurable difference. The overlap of liver and kidney failure creates a cluster of management challenges that reinforce each other:

Hepatic encephalopathy: Confusion and altered consciousness from ammonia buildup can worsen when the kidneys can no longer help clear toxins. Treatments include lactulose to reduce ammonia, careful correction of low sodium levels, and in some cases continuous kidney-support therapy to lower ammonia directly.²¹
Fluid and electrolyte imbalance: Cirrhosis drives the body to retain sodium and water, producing massive abdominal fluid accumulation. Kidney failure compounds this by making it harder to excrete extra fluid and correct dangerously low sodium.²²
Infection prevention: Patients with both failing organs are highly vulnerable to infections, which can tip them into ACLF. Monitoring for infection and acting quickly with antibiotics is central to keeping patients stable.²³

Dialysis can be used when the kidneys fail completely, but it comes with its own problems in cirrhosis patients. Standard hemodialysis often causes dangerous drops in blood pressure, because these patients already have unstable circulation.²⁴ Continuous kidney-support methods, which work more gently over longer periods, tend to be better tolerated in the intensive care setting. Experimental devices like the MARS system (molecular adsorbent recirculating system), which filters both water-soluble and protein-bound toxins, have shown some ability to extend survival in small trials, though they remain far from widely available.²⁵

The Role of Underlying Causes

What caused the cirrhosis in the first place can shape the kidney story. Metabolic-associated fatty liver disease (commonly linked to obesity and type 2 diabetes) is increasingly recognized as a driver of both liver and kidney problems through shared pathways involving insulin resistance, inflammation, and cardiovascular disease.²⁶ Among patients with type 2 diabetes and chronic kidney disease, those who also have fatty liver disease face a roughly doubled risk of progressing to end-stage kidney disease.²⁷ In these patients, kidney failure may not be purely a consequence of cirrhosis’s blood-flow problems; the metabolic damage is hitting both organs independently. That distinction matters because treating only the liver may not be enough to rescue the kidneys when structural kidney disease is already present.

A Gender Gap in Access to Transplantation

One underappreciated factor that can indirectly affect survival is sex. The MELD score, which determines a patient’s priority on the transplant waiting list, relies on serum creatinine as a proxy for kidney function. Women naturally produce less creatinine than men due to differences in muscle mass. At the same actual level of kidney filtration, a woman’s creatinine reading will be lower than a man’s, which means her MELD score will be lower, and she will wait longer for a transplant.²⁸ This built-in bias means women with cirrhosis and kidney failure may face longer waits and higher waiting-list mortality than men with equivalent disease severity. The issue has been recognized for years, but the scoring system has been slow to change.

When Transplant Is Not an Option

For patients who are not candidates for transplantation, the conversation eventually shifts toward quality of life. Advanced liver and kidney disease together produce a heavy burden of symptoms: pain, massive abdominal swelling, confusion, extreme fatigue, itching, and nausea. Palliative care teams specialize in managing these symptoms and helping patients and families make informed decisions about the goals of continued treatment.²⁹ Despite the clear need, palliative care is underused in both liver and kidney disease. Many patients are referred only in the final days, missing months of potential symptom relief and support. If you or a family member is dealing with advanced cirrhosis and kidney failure and transplant is off the table, asking about palliative care early rather than late can make a meaningful difference in comfort and clarity during the time that remains.

1
Europe PMC. Hepatorenal Syndrome: A Review of Pathophysiology and Current Treatment Options
2
Gastroenterology. Prognostic Importance of the Cause of Renal Failure in Patients With Cirrhosis
3
Nature Reviews Disease Primers. Hepatorenal syndrome
4
PubMed. Hepatorenal syndrome: pathophysiology, diagnosis, and management
5
PubMed. MELD score and clinical type predict prognosis in hepatorenal syndrome: relevance to liver transplantation
6
Wiley Online Library. Hepatorenal Syndrome: Outcome of Response to Therapy and Predictors of Survival
7
PubMed Central. Acute Kidney Injury in Patients with Liver Cirrhosis: Prevalence, Predictors, and In-Hospital Mortality at a District Hospital in Ghana
8
Hepatology. Acute kidney injury in cirrhosis
9
PubMed. Albumin infusion improves renal blood flow autoregulation in patients with acute decompensation of cirrhosis and acute kidney injury
10
PubMed Central. Albumin: Indications in chronic liver disease
11
PubMed. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study
12
PubMed. Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial
13
PubMed Central. Terlipressin and albumin combination treatment in patients with hepatorenal syndrome type 2
14
PubMed. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis
15
Digestive and Liver Disease. Transjugular intrahepatic portosystemic shunt for hepatorenal syndrome: A systematic review and meta-analysis
16
PubMed Central. Changes in Kidney Function After Transjugular Intrahepatic Portosystemic Shunts Versus Large-Volume Paracentesis in Cirrhosis: A Matched Cohort Analysis
17
PubMed. Predictors of renal recovery in recipients of liver transplant alone who met 2017 simultaneous liver-kidney transplant criteria
18
American Journal of Transplantation. Developing simultaneous liver-kidney transplant medical eligibility criteria while providing a safety net: A 2-year review of the OPTN’s allocation policy
19
Nature Reviews Disease Primers. Acute-on-chronic liver failure in cirrhosis
20
Clinical Medicine. Acute-on-chronic liver failure
21
PubMed. Management of hepatic encephalopathy
22
PubMed. Kidney Injury and Electrolyte Abnormalities in Liver Failure
23
PubMed. Critical care management of acute liver failure
24
PubMed. Outcomes of peritoneal dialysis in cirrhosis: A systematic review and meta-analysis
25
PubMed. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial
26
Nefrología (English Edition). Targeting metabolic-associated fatty liver disease in diabetic kidney disease: A call to action
27
PubMed. Impact of non-alcoholic fatty liver disease and fibrosis on mortality and kidney outcomes in patients with type 2 diabetes and chronic kidney disease: A multi-cohort longitudinal study
28
PubMed Central. Gender Disparity in Liver Transplant Waiting List Mortality: The Importance of Kidney Function
29
Advances in Kidney Disease and Health. Palliative Care in Kidney and Liver Diseases